Chronic Lymphoproliferative Diseases (CLPD)
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Becton DickinsonFRANKLIN LAKES, NJ
2 programsBD OneFlow LST, and B-CLPD T1 to T4 AssaysN/A1 trial
IUO CLPD Limited PanelN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Becton DickinsonBD OneFlow LST, and B-CLPD T1 to T4 Assays
Becton DickinsonIUO CLPD Limited Panel
Clinical Trials (2)
Total enrollment: 693 patients across 2 trials
BD OneFlow CLPD Panel (BD OneFlow LST, and B-CLPD T1 to T4 Assays) on the BD FACSLyric System.
Start: Oct 2022Est. completion: May 2024322 patients
N/ACompleted
Evaluation of the Chronic Lymphoproliferative Diseases Limited Panel on the BD FACSLyric™ Flow Cytometer
Start: Apr 2021Est. completion: Dec 2023371 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.